These findings suggested that miR-126 and miR-133b might play a key role in the progression and metastasis of non small cell lung cancer

miR-133 involves in lung adenocarcinoma cell metastasis by targeting FLOT2

Overexpression of miR-133b inhibited the growth and proliferation of lung cancer stem cells by down regulating PKM2.

The present study findings provide the insights that miR133b reduces cisplatin resistance and its overexpression contributes to the suppression of the malignant growth and aggressiveness of cisplatinresistant nonsmall cell lung cancer cells by targeting GSTP1.

Low miR133b expression is associated with drug resistance in non-small cell lung cancer.

MiR-133b levels were downregulated in normal tissues compared to both paraffin and frozen non-small cell lung cancer (NSCLC) samples, and correlated with both HuR and TTP expression, which may affect the prognosis of NSCLC patients.

The detection of miR-133b expression levels in tumors help in the identification of non-small cell lung cancer patients with a better prognosis and who are likely to benefit from second and third-line therapy with erlotinib.

HOXD-AS1 was upregulated in non-small cell lung carcinoma tissues and cell lines and promoted NSCLC cell proliferation, migration invasion via sponging miR-133b and regulating MMP9.